Alhagi/MSC may protect the colonic barrier in mice by preserving tight-junction proteins, and may alleviate dextran sulfate sodium (DSS)-induced ulcerative colitis in mice by inhibiting the abnormal activation of the NLRP3 inflammasome pathway and TNF signaling pathway, thereby reducing colon damage. Here, NLRP3 is linked to ulcerative colitis.